13 November 2026 ASX Announcement Investor webinar MELBOURNE Australia, 13 November 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to invite shareholders and investors to attend an investor webinar on...
Investor webinar
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has announced an upcoming investor webinar. The webinar will cover updates on the Galidesivir development program and upcoming studies. Management will discuss objectives and timelines for the Marburg dose optimisation study. An interactive Q&A session will follow the presentation for shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- NHP Surgeries Commence Ahead of Galidesivir Marburg Study
- Quarterly Appendix 4C and Activities Report
- Letter to Shareholders, Notice of AGM & Proxy Form
- USAMRIID Marburg study advances towards dosing
- Notification regarding unquoted securities - ILA
Later from Island Pharmaceuticals
All Island Pharmaceuticals news releasesFollow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals